Dr. Sperling received his medical degree and PhD in Biological Chemistry from the University of California, Los Angeles in 2011. He completed his residency in internal medicine at the Brigham and Women's Hospital and his fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. He received board certification from the American Board of Internal Medicine in 2014 and the American Board of Medical Oncology in 2017. In 2018, he joined the staff of the Dana-Farber Cancer Institute, where he is a medical oncologist and basic and translational researcher in hematologic malignancies.

His research focuses on understanding the mechanisms of disease evolution from pre-malignant conditions and the development of drug resistance in multiple myeloma and other hematologic malignancies.

Dr. Sperling received his medical degree and PhD in Biological Chemistry from the University of California, Los Angeles in 2011. He completed his residency in internal medicine at the Brigham and Women's Hospital and his fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. He received board certification from the American Board of Internal Medicine in 2014 and the American Board of Medical Oncology in 2017.In 2018, he joined the staff of the Dana-Farber Cancer Institute, where he is a medical oncologist and basic and translational researcher in hematologic malignancies.